Skip to main content
Premium Trial:

Request an Annual Quote

Bruker and PNNL to Enhance Fourier Transform Mass Spec for Proteomics

NEW YORK, June 9 - Bruker Daltonics said today that it has signed a Cooperative Research and Development Agreement (CRADA) with Battelle Memorial Institute, the operating and management contractor for the Department of Energy's Pacific Northwest National Laboratory, to develop and commercialize Fourier transform mass spectrometry for high-throughput proteomics research.


The CRADA, announced at the American Society for Mass Spectrometry conference in Montreal, is the second between Bruker and Battelle/PNNL. In 2000, the two organizations signed a first CRADA on the co-development of a hybrid Q-q-FTMS system for proteomics research, which formed the basis of Bruker's recently launched APEX-Q FTMS.


The new agreement will focus on the further development and commercialization of methods for enhancing the dynamic range of FTMS, Bruker said. The partnership will build upon a technique known as Dynamic Range Enhancement for Advanced Mass Spectrometry (DREAMS) developed by Richard Smith's group in the Environmental Molecular Sciences Laboratory at PNNL.


PNNL will have access to Bruker's APEX-Q hybrid FTMS in order to facilitate the transfer of DREAMS to a commercial instrument, the company said.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.